Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality

Journal of the National Cancer Institute - Monographs

Volumn , Issue 46, 2013, Pages 117-123

  Etzioni, Ruth ^a   Durand Zaleski, Isabelle ^b   Lansdorp Vogelaar, Iris ^c  

^a USA   (United States)

^b HENRI MONDOR HOSPITAL   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; DISEASE SURVEILLANCE; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR BIOPSY; ADULT; AGED; BIOPSY; BLOOD; COST BENEFIT ANALYSIS; DISEASE COURSE; EARLY DIAGNOSIS; ECONOMICS; INCIDENCE; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; PROSTATIC NEOPLASMS;

ADULT; AGED; BIOPSY; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84883047517     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgt010     Document Type: Article

References (30)

1. Mariotto AB, Etzioni R, Krapcho M, Feuer EJ. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 2007;109(9): 1877-1886.
2. Andriole GL, Crawford ED, Grubb RL III, et al.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-1319.
3. Schröder FH, Hugosson J, Roobol MJ, et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
4. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
5. Berry DA, Cronin KA, Plevritis SK, et al.; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.
6. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-573.
7. Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control. 1998;9(5):519-527.
8. Division of Cancer Control and Population Sciences, National Cancer Institute. SEER*Stat Database: Incidence - SEER 9 Regs Limited-Use, Nov 2010 Sub (1973-2009). Bethesda, MD: National Cancer Institute; 2012. http://seer.cancer.gov/data/. Accessed May 9, 2013.
9. National Center for Health Statistics. SEER*Stat Database: Mortality - All COD, Public-Use With State, Total U.S. (1969-2005). Bethesda, MD: National Cancer Institute; 2008. http://seer.cancer.gov/mortality/. Accessed May 9, 2013.
10. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95(13):981-989.
11. Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics. 2010;11(4):707-719.
12. Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst. 1995;87(5):354-360.
13. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267(16):2215-2220.
14. Inoue LYT, Etzioni R, Morrell C, et al. Modeling disease progression with longitudinal markers. J Am Stat Ass. 2008;103(481):259-270.
15. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224.
16. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158(3):145-153.
17. Gulati R, Wever EM, Tsodikov A, et al. What if I don't treat my PSAdetected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev. 2011;20(5):740-750.
18. Bill-Axelson A, Holmberg L, Ruutu M, et al.; Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977-1984.
19. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295-300.
20. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118(23):5955-5963.
21. Feuer EJ, Wun LM. How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach. Am J Epidemiol. 1992;136(12):1423-1436.
22. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-990.
23. Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2008;64(1):10-19.
24. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.
25. Vickers AJ, Wolters T, Savage CJ, et al. Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. J Urol. 2010;184(3):907-912.
26. Ekwueme DU, Stroud LA, Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prev Chronic Dis. 2007;4(4):A100.
27. Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
28. Zauber AG, Lansdorp-Vogelaar I. Changes in risk factors and increases in screening contribute to the decline in colorectal cancer mortality, 1975 to 2000. Gastroenterology. 2010;139(2):698.
29. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(9):659-669.
30. Mandelblatt JS, Cronin KA, Bailey S, et al.; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738-747.